Author: Charmaine Fraser

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has completed a placing, conditional on certain resolutions being passed at a general meeting of the Company (the “General Meeting”) and admission to trading on AIM, of, in aggregate, £449,999.88 (gross) from the issue of 149,999,960...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, today announces its unaudited financial results for the six months ended 31 December 2025.   Please click here to read in full....

TR-1: Standard form for notification of major holdings Please click here to read in full...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new biopharmaceutical client headquartered in South Korea.   This new project is with a South Korean clinical stage biopharmaceutical company focused on the development of next-generation antibody drug conjugate (ADC) and Immuno-oncology therapeutic for the...

TR-1: Standard form for notification of major holdings Please click here to read in full...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG (“Numab Therapeutics”).   This project reflects the continued application of Physiomics’ modelling expertise across Numab Therapeutics’ pipeline to accelerate the development of innovative therapies, building further on the...

Physiomics plc (AIM: PYC), announces an award of share options (the “Options”) over ordinary shares of 0.4 pence each in the capital of the Company (“Ordinary Shares”). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a follow on contract with an existing UK based-client.   This new project builds on the contract award announced on 9 May 2025, under which Physiomics assisted its client in developing a population Pharmacokinetic (PK) model to inform the design...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG.   This latest project will use modelling and simulation approaches to support the pre-clinical development of a multi-specific antibody in the Numab Therapeutics pipeline, under development for the...